Bone Biologics Corporation
BBLG
$1.16
-$0.05-4.13%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.66% | 1.19% | 21.19% | -6.54% | -36.82% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -52.85% | -24.78% | -7.61% | 14.94% | 34.04% |
| Operating Income | 52.85% | 24.78% | 7.61% | -14.94% | -34.04% |
| Income Before Tax | 55.01% | 29.15% | 5.51% | -17.45% | 1.82% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 55.01% | 29.15% | 5.51% | -17.45% | 1.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 55.01% | 29.15% | 5.51% | -17.45% | 1.82% |
| EBIT | 52.85% | 24.78% | 7.61% | -14.94% | -34.04% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 89.68% | 97.39% | 67.00% | 75.61% | 81.83% |
| Normalized Basic EPS | 89.68% | 88.46% | 67.00% | 75.61% | 75.19% |
| EPS Diluted | 89.68% | 97.39% | 67.00% | 75.61% | 81.83% |
| Normalized Diluted EPS | 89.68% | 88.46% | 67.00% | 75.61% | 75.19% |
| Average Basic Shares Outstanding | 335.92% | 514.13% | 186.34% | 381.40% | 440.39% |
| Average Diluted Shares Outstanding | 335.92% | 514.13% | 186.34% | 381.40% | 440.39% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |